Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8985039 | 1.00 | GPR84 (0.32) | GPR84FFAR1HSPD1BLMHSPE1 | |
| SCHEMBL8985117 | 0.79 | LCK (0.38) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL7293488 | 0.79 | CA2 (0.39) | GPR84FFAR1BLMLTB4R | |
| SCHEMBL9766905 | 0.77 | GPR84 (0.31) | GPR84LTB4R | |
| SCHEMBL7326578 | 0.77 | ALDH1A1 (0.38) | LTB4R | |
| SCHEMBL9744651 | 0.77 | ALDH1A1 (0.32) | MAPT | |
| SCHEMBL9803456 | 0.76 | GLS2 (0.34) | LTB4R | |
| SCHEMBL9677956 | 0.75 | — | — | |
| SCHEMBL9159891 | 0.75 | FAAH (0.35) | MAPT | |
| SCHEMBL9160196 | 0.75 | FAAH (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5541221-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0637240-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES FOR INHIBITING BONE LOSS | ALLERGAN, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5387606-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN, INC. (US) | 1995-02-07 | — | — | US | disclosed |
| US-5268387-A | Containing ester or carbamate group | ALLERGAN, INC. (US) | 1993-12-07 | — | — | US | disclosed |
| WO-1993021915-A1 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING BONE LOSS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES | ALLERGAN, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
| US-5169963-A | Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents | ALLERGAN, INC. (US) | 1992-12-08 | — | — | US | disclosed |